ArticleScientific reports2025
Intraperitoneal immune microenvironment and efficacy of intraperitoneal chemotherapy in patients with gastric cancer and peritoneal metastasis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Plasma proteomics-based liquid biopsy for predicting efficacy of PD-1-based immunochemotherapy in advanced gastric cancer: a prospective cohort study.Molecular biomedicine · 2026Article
- Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges.International journal of cancer · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the role of the intraperitoneal immune microenvironment in the therapeutic response of gastric cancer with peritoneal metastasis to intraperitoneal paclitaxel. Gastric cancer with peritoneal metastasis has a poor prognosis, even with systemic chemotherapy. Although intraperitoneal paclitaxel administration has demonstrated clinical benefit, treatment resistance remains a major hurdle. Between 2017 and 2023, 30 patients undergoing staging laparoscopy were prospectively enrolled. Immune cell subsets and checkpoint marker expression in peritoneal lavage fluid were analyzed using flow cytometry and immunohistochemistry. Their associations with clinical outcomes were assessed using univariable and multivariable analyses, including Kaplan-Meier, logistic regression, and Ridge regression analyses. Elevated CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.